Analyst Reco. Teva Pharmaceutical Industries Limited London S.E.

Equities

0LER

US8816242098

Market Closed - London S.E. Other stock markets 16:30:00 31/05/2024 BST			5-day change	1st Jan Change
16.9 ^USD	+3.21%		+1.19%	+61.95%

05-30	Teva Pharmaceutical Gains FDA Approval for Daily Huntington's Disease Pill	MT
05-30	Teva Pharmaceutical Industries Limited Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24?48 mg/day)	CI

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Teva Pharmaceutical Industries Insider Sold Shares Worth $470,794, According to a Recent SEC Filing	05-17	MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $254,807, According to a Recent SEC Filing	05-15	MT
Piper Sandler Adjusts Price Target on Teva Pharmaceutical Industries to $20 From $19, Maintains Overweight Rating	05-13	MT
JPMorgan Upgrades Teva Pharmaceutical Industries to Neutral From Underweight, Adjusts Price Target to $14 From $11	03-08	MT
Piper Sandler Upgrades Teva Pharmaceutical Industries to Overweight From Neutral, Adjusts PT to $19 From $12	02-12	MT
Goldman Sachs Adjusts Price Target on Teva Pharmaceutical Industries to $11 From $10, Maintains Neutral Rating	02-05	MT
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $17 From $15, Maintains Overweight Rating	02-05	MT
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $15 From $14, Maintains Overweight Rating	01-29	MT
Teva: share price up, broker in support	01-23	CF
TEVA : Jefferies raises its recommendation	01-23	CF
Jefferies Upgrades Teva Pharmaceutical Industries to Buy From Hold, Raises Price Target to $14 From $10	01-23	MT
BofA Securities Adjusts Teva Pharmaceutical Industries Price Target to $14 From $13, Maintains Buy Rating	01-12	MT
Piper Sandler Upgrades Teva Pharmaceutical Industries to Neutral From Underweight, Raises Price Target to $12 From $8	01-03	MT
HSBC Initiates Teva Pharmaceutical Industries at Buy Rating With $13 Price Target	12-18	MT
UBS Upgrades Teva Pharmaceutical Industries to Buy From Neutral, Adjusts Price Target to $13 From $11	11-27	MT
UBS Upgrades Teva Pharmaceutical Industries to Neutral From Sell, Raises Price Target to $8 From $7	06/07/23	MT
Evercore ISI Upgrades Teva Pharmaceutical Industries to Outperform From In-Line	18/05/23	MT
Barclays Adjusts Teva Pharmaceutical Industries Price Target to $14 From $13, Maintains Overweight Rating	09/02/23	MT
Jefferies Downgrades Teva Pharmaceutical Industries to Hold From Buy, Adjusts Price Target to $12 From $10	19/01/23	MT
UBS Downgrades Teva Pharmaceutical Industries to Sell From Neutral, Adjusts Price Target to $7 From $10	04/11/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Teva Pharmaceutical Industries isn't out of the woods yet

February 01, 2024 at 09:41 am

INTERVIEW - Richard Francis, CEO of Teva Pharmaceutical: solid quarter, full-year forecasts raised

August 02, 2023 at 08:19 pm